Fintel reports that on September 18, 2023, Citigroup maintained coverage of Rain Oncology (NASDAQ:RAIN) with a Neutral recommendation.
Analyst Price Forecast Suggests 477.01% Upside
As of August 31, 2023, the average one-year price target for Rain Oncology is 4.74. The forecasts range from a low of 1.01 to a high of $17.85. The average price target represents an increase of 477.01% from its latest reported closing price of 0.82.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Rain Oncology is 0MM. The projected annual non-GAAP EPS is -1.90.
What is the Fund Sentiment?
There are 124 funds or institutions reporting positions in Rain Oncology. This is an increase of 25 owner(s) or 25.25% in the last quarter. Average portfolio weight of all funds dedicated to RAIN is 0.02%, a decrease of 85.16%. Total shares owned by institutions decreased in the last three months by 20.34% to 17,067K shares. 
The put/call ratio of RAIN is 0.15, indicating a bullish outlook.
What are Other Shareholders Doing?
Tang Capital Management holds 3,740K shares representing 10.28% ownership of the company.
Bvf holds 3,527K shares representing 9.70% ownership of the company. No change in the last quarter.
Samsara BioCapital holds 2,035K shares representing 5.59% ownership of the company. In it's prior filing, the firm reported owning 2,261K shares, representing a decrease of 11.11%. The firm decreased its portfolio allocation in RAIN by 89.51% over the last quarter.
Boxer Capital holds 1,152K shares representing 3.17% ownership of the company. In it's prior filing, the firm reported owning 2,147K shares, representing a decrease of 86.36%. The firm decreased its portfolio allocation in RAIN by 93.04% over the last quarter.
Acadian Asset Management holds 659K shares representing 1.81% ownership of the company. In it's prior filing, the firm reported owning 3K shares, representing an increase of 99.58%. The firm increased its portfolio allocation in RAIN by 2,985.94% over the last quarter.
Rain Therapeutics Background Information
(This description is provided by the company.)
Rain Therapeutics Inc. is a clinical-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, RAIN-32 (milademetan, formerly known as DS-3032), is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to RAIN-32, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
